MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:
THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that the Klinikum Stephansplatz-Hamburg (Germany) has signed a commercial agreement and will now offer Echotherapy to its patients. To support Theraclion’s growth and commercial momentum, the company also announces the appointment of Laurence Aucoin as Vice President Operations.
Adoption of Theraclion Echotherapy solution by the Klinikum Stephansplatz-Hamburg
The Klinikum Stephansplatz-Hamburg is a large private clinic specializing in interdisciplinary internal medicine. Seventeen medical specialties collaborate to ensure rapid, accurate diagnosis and immediately available, individualized therapy. Many of the doctors who work at the Klinikum also have teaching activities in the surrounding university medical centers. Klinikum Stephansplatz performs around 2000 thyroid diagnostics per year.
For the first time in Germany, the Echotherapy system will be implemented in an endocrinology service, which will make Klinikum Stephansplatz-Hamburg a reference center for this specialty performing around 2000 thyroid diagnostics per year. The other centers in Germany have deployed their Echotherapy capability within Nuclear Medicine, Thyroid Surgery, or Surgical Gynecology (breast) units. The Hamburg center is the 9th German Echotherapy center.
Klinikum Stephansplatz is a partner in the network of the Gesundheitsverbund Nord (GVN), the largest network of healthcare actors in Northern Germany, including insurance companies.
“We are very happy to be able to offer our patients this innovative, non-invasive therapy option,” says Dr. Ahmadi-Simab, Medical Director of the Klinikum Stephansplatz.
“I’m confident the Klinikum Stephansplatz will be an important driver of Echotherapy treatments. Dr. Ahmadi-Simab’s teams will be able to work with insurance companies to provide patients access to this non-invasive alternative to surgery,” adds Matthias Heilmann, CEO of GVN.
Nomination of Laurence Aucoin to support the sales’ growth
To support Theraclion’s growth in Germany and beyond, the company also announces the appointment of Laurence Aucoin as Vice President Operations. In this position, Laurence will oversee Theraclion’s production and service activities developing the capabilities the company will need to match its ambitions and potential.
Prior to her appointment, Laurence held various leadership positions in production and service over 25 years at General Electric (GE). For seven years, Laurence led GE’s mammography product line service effort managing upgrade deployment programs for the installed base and introducing non-obsolescence programs. Laurence holds a Biomedical Engineering degree from UTC (University of Technology of Compiègne - France).
“I’ve known Laurence for many years and she is a dynamic leader with a proven track record,” says David Caumartin, CEO of Theraclion. “Her experience and expertise are helping us build the infrastructure we need to grow fast and not only meet our customers’ expectations but also exceed them."
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
Mnemonic: ALTHE - ISIN Code: FR0010120402